Bringing the Oncology Community Together
Giants of Cancer Care 2015
FDA Accepts NDA for TAS-102 in mCRC
The FDA has accepted an NDA for the oral nucleoside TAS-102 as a treatment for patients with refractory metastatic colorectal cancer.
Read More >>
Analysis Confirms Safety of Regorafenib in mCRC Among Best Responders
Questions Remain Regarding Combinations and Sequencing in pNETs
Multitargeted Drug Slows CRC as Third-Line Therapy
Monocyte-Targeting Agent Active in Locally Advanced Pancreatic Cancer
Lanreotide Effective in Pancreatic NET Subgroup
Expanded NAPOLI-1 Analysis Further Characterizes MM-398 Benefit in Metastatic Pancreatic Cancer
View More >>
- A Network of Your Peers
View more >>
Dr. Cremolini on Identifying Molecular Markers in mCRC
Exercise and Lifestyle Factors in Patients with mCRC
Adjuvant Therapy in Stage II Colon Cancer
Most Popular Right Now
Tweets by @OncLive
New Metastatic Colorectal Cancer iPub
Insight from Fadi Braiteh, MD, and Robin Wachsman, RN, BS, OCN, CCRN, CBCN, on regorafenib in mCRC.
Treatment Considerations in Refractory CRC
Moderated by John L. Marshall, MD, this panel discussion includes expert perspectives from Johanna Bendell, MD, Marwan Fakih, MD, Heinz-Josef Lenz, MD, and Alan P. Venook, MD.
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
666 Plainsboro Road
Plainsboro, NJ 08536
Copyright OncLive 2006-2015
Intellisphere, LLC. All Rights Reserved.